Lurbinectedin not checked

Jazz Pharmaceuticals · JZP712

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
5 active
9 in total · 5 in the EU
Targets
 

What this is

How it works
Alkylating Drug FDA class
How it’s given
“Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)”In the company’s words, NCT06496048 on ClinicalTrials.gov
Tested for
Relapsed Small Cell Lung Cancer, Leiomyosarcoma, Extensive-stage Small-cell Lung Cancer, Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Main trialPhase 3
“Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of Lurbinectedin monotherapy or Lurbinectedin + Irinotecan combined therapy versus Topotecan comparator in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.”In the company’s words, NCT06496048 on ClinicalTrials.gov
Other names
JZP712 · Zepzelca

Other drugs for Relapsed Small Cell Lung Cancer

All 118 drugs for Relapsed Small Cell Lung Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2027 Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Phase 3Active, not recruiting 30 Aug 2029 Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Phase 2Recruiting 4 Aug 2029 A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Phase 1/2Recruiting 28 Jan 2028 Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Phase 2Terminated 20 Dec 2023 Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Phase 1/2Ended not given Phase I-II Study to Assess the Safety, Tolerability and Efficacy of Lurbinectedin and Dostarlimab in Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy. LiDer trial
Phase 1/2Ended not given “Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer (the LUPER study).”
Phase 1/2Ended not given Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy
Phase 2Authorised not given Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lurbinectedin

Following is part of Solo: you see every change to Lurbinectedin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in